There was a time when the numbers informed an unoptimistic story about Roche. Its three oncology blockbusters, Herceptin, Avastin, and Rituxan, had constructed it into the world’s largest most cancers drug maker, collectively producing round $21 billion in annual gross sales at their peak. Then, biosimilars arrived. Deutsche Financial institution warned that Roche had $22 billion in revenues uncovered to competitors. In 2018, JP Morgan analysts forecast double-digit declines for its greatest merchandise. When the erosion hit, it got here more durable and quicker than Roche’s projections had anticipated; the $9.6 billion hole the corporate had modeled between 2018 and 2023 gross sales was crossed by 2021.
However Roche grew via it, as a brand new era of medicines – Ocrevus in a number of sclerosis, Hemlibra in hemophilia, and Vabysmo in retinal illness – absorbed the hit. By 2025, its prime 5 progress drivers had been pulling in over $20 billion in mixed gross sales.
However what has Roche chosen to do subsequent? Past consolidating round its present strengths, the corporate has launched a second strategic reinvention: coming into weight problems, inserting a $7.1 billion guess on a novel inflammatory bowel illness (IBD) mechanism, and buying an allogeneic cell remedy platform, all inside roughly two years.
What the Roche we all know immediately was constructed on
The corporate that exists immediately is the product of two choices made a long time aside. In 1990, Roche acquired a 60% stake within the California biotech Genentech. The total buyout got here in 2009, when Roche paid $46.8 billion for the remaining publicly held shares, on the time the most important acquisition in Swiss company historical past.
The acquisition wasn’t as easy as it might appear. When Roche moved to purchase out Genentech’s minority shareholders in July 2008, the preliminary supply of $89 per share triggered a right away shareholder backlash. A category motion lawsuit was filed alleging breach of fiduciary obligation, with plaintiffs arguing Roche had intentionally timed the bid to use market turmoil and a weakened greenback. The litigation was finally settled, however not earlier than Roche was compelled to boost its bid to $95 per share.
For that worth, Roche obtained greater than only a drug portfolio; it obtained the platform that produced Herceptin, Avastin, and Rituxan, the oncology trio that might come to outline the corporate’s business identification for the subsequent twenty years.
Herceptin modified HER2-positive breast most cancers remedy. Avastin grew to become an ordinary of care throughout a number of tumor varieties. Rituxan dominated blood most cancers and later moved into autoimmune illness. They established Roche because the world’s largest oncology firm, a place it held for years on the again of medicines that got here nearly completely from Genentech’s labs.
The opposite defining choice got here earlier, in 1997, when Roche acquired Boehringer Mannheim for $11 billion. It gave Roche a diagnostics enterprise to sit down alongside its pharma enterprise, at a time when most of its opponents had been treating diagnostics as a secondary concern. The logic was that if you happen to can develop the focused remedy and the diagnostic take a look at that identifies which sufferers will reply to it, you management each ends of the remedy choice.
This grew to become the inspiration of what Roche calls customized healthcare, an idea the corporate has used to border its technique for many years.
The Roche disaster: biosimilar erosion
In September 2019, Invoice Anderson, CEO of Roche Pharmaceutical Division on the time, was estimating 60 to 70% erosion throughout Herceptin, Avastin, and Rituxan, which he referred to as a “conservative” projection. The corporate was trying at a CHF 9.6 billion ($11.8 billion) gross sales hole between 2018 and 2023.
The dynamic was completely different from a standard small-molecule patent cliff. Biosimilars to biologics face a slower and extra complicated uptake as a consequence of doctor inertia, switching prices, and payer dynamics, all of which sluggish the erosion in comparison with generic medicine. Nonetheless, by Q1 2022, Avastin had shed 32% of its gross sales year-on-year, Herceptin 19%, and Rituxan 21%.
On one facet, Roche operated a deliberate pipeline rationalization: in early 2024, the corporate reduce eight early- to mid-stage candidates. 5 from neurology and three in oncology and hematology had been discontinued as a part of what CEO Thomas Schinecker described as a reallocation of assets towards packages with the clearest differentiation.
On the opposite facet, Roche made partnerships and acquisitions of de-risked exterior belongings, with Schinecker stating that Roche was trying to purchase drug belongings in any respect phases of improvement.
The brand new blockbusters that stuffed the hole
In 2025, Roche’s new 5 principal progress drivers, Ocrevus, Hemlibra, Vabysmo, Phesgo, and Xolair, generated mixed gross sales of CHF 21.4 billion ($26.4 billion), up CHF 3.2 billion ($3.9 billion) from 2024.
Ocrevus, an anti-CD20 antibody for a number of sclerosis authorised in 2017, is Roche’s greatest vendor at CHF 7.01 billion ($8.6 billion) in 2025. Hemlibra, a bispecific antibody for hemophilia A, reached CHF 4.8 billion ($5.9 billion), up 11% year-on-year. Vabysmo, a dual-targeting antibody for retinal ailments, launched in early 2022 and have become one in all Roche’s fastest-growing merchandise.
The corporate made cautious bets in areas the place it had experience. Ocrevus prolonged Roche’s present antibody experience into a brand new indication. Hemlibra and Vabysmo each used the bispecific antibody format, a platform Roche had been creating internally for years. Phesgo was a lifecycle administration of the HER2 franchise.
Dealmaking as a progress engine for Roche
Since 2023, Roche has deployed important capital in the direction of dealmaking. On the JPMorgan Healthcare Convention in January 2025, Roche Pharmaceutical Division’s CEO Teresa Graham stated Roche has roughly $10 billion in M&A firepower it could deploy every yr, and is able to use it “if and once we discover transformative belongings which might be both complementary to our portfolio or change the sport in necessary ailments.”
Throughout completely different therapeutic areas, two varieties dominate in Roche’s dealmaking technique. The primary is large-scale acquisitions of late-stage or phase-3-ready belongings the place the scientific threat is considerably de-risked.
First, Telavant in October 2023 for $7.1 billion upfront, plus a $150 million near-term milestone, giving Roche U.S. and Japan rights to afimkibart, an anti-TL1A antibody with robust part 2b information in ulcerative colitis and a novel mechanism concentrating on each irritation and fibrosis.
Six weeks later, Carmot Therapeutics for $2.7 billion upfront plus as much as $400 million in milestones, bringing three clinical-stage weight problems candidates, together with CT-388, a phase-2-ready twin GLP-1/GIP agonist.
Then, 89bio in September 2025, $2.4 billion upfront and as much as $3.5 billion complete, for pegozafermin, an FGF21 analog in part 3 for MASH.
The second deal kind is smaller and extra focused. Poseida Therapeutics in November 2024 for as much as $1.5 billion, bringing an allogeneic CAR-T platform constructed on non-viral, T stem cell memory-rich engineering, a know-how Roche had already been partnering with since 2022.
Regor Therapeutics in September 2024 for $850 million upfront, technically an asset buy via Genentech, bringing two next-generation CDK inhibitors for breast most cancers, positioned as potential successors to the CDK4/6 inhibitor class. And in March 2025, the Zealand Pharma collaboration: $1.65 billion upfront towards a complete potential worth of $5.3 billion to co-develop petrelintide, an amylin analog being positioned as a mix companion for CT-388 in weight problems.
These offers symbolize commitments of nicely over $15 billion in upfront capital throughout roughly two years, in IBD, weight problems, metabolic dysfunction-associated steatohepatitis (MASH), cell remedy, and breast most cancers oncology.
How is Roche strategically positioned?
Essentially the most formidable growth Roche has operated up to now few years is likely to be in the direction of weight problems. Nevertheless it has additionally invested considerably in immunology, in addition to neuroscience.
Roche’s weight problems pipeline: essentially the most audacious guess
Roche’s weight problems pipeline technique seems to be like a portfolio guess on the place the market will probably be in 5 to seven years. The lead asset is CT-388, a once-weekly injectable twin GLP-1/GIP receptor agonist, the identical mechanistic class as Eli Lilly’s Zepbound. In January 2026, Roche printed part 2 information displaying placebo-adjusted weight lack of 22.5% at 48 weeks on the highest dose examined, with out reaching a plateau. Two part 3 trials are actually underway, initiated in Q1 2026.
The timing may not be essentially the most handy, as CT-388 is coming into part 3 at some extent when Wegovy and Zepbound have already got years of business infrastructure, doctor familiarity, and affected person uptake behind them. Even when the part 3 trials ship, Roche is behind its competitors.
Roche’s reply to that timing drawback is the mixture technique. The weight problems market immediately is dominated by single-agent GLP-1s, however their key limitation is tolerability, with nausea driving most discontinuation, and considerations about muscle mass loss on long-term remedy. Roche is betting that by the point it arrives, mixtures addressing these limitations would be the new commonplace.
Petrelintide, acquired through the $1.65 billion upfront Zealand Pharma collaboration, is an amylin analog designed to enhance GLP-1 remedy by lowering nausea and preserving lean mass, with a mix research with CT-388 deliberate for the primary half of 2026.
Nonetheless, not all bets can go all the best way, and in March 2026, Roche introduced it might discontinue Emugrobart, an anti-myostatin antibody meant to handle lean mass preservation that was examined together with Mounjaro.
Bowel illness and immunology: inside Roche’s $7 billion guess on TL1A
IBD is a big and commercially lively market, however it stays one the place present therapies fall wanting what sufferers want. Regardless of a era of biologics, TNF inhibitors, IL-12/23 antibodies, and integrin blockers, most sufferers with ulcerative colitis or Crohn’s illness don’t obtain lasting remission. That is what made TL1A, a cytokine concerned in each irritation and fibrosis, one of the intently watched targets in immunology over the previous few years.
TL1A is distinct from most present IBD targets as a result of it drives immune activation along with fibrosis, the scarring that causes long-term issues in Crohn’s illness. An antibody that addresses each processes might do greater than present biologics. That’s the guess behind afimkibart, the anti-TL1A antibody Roche acquired with Telavant. Part 3 trials in ulcerative colitis are ongoing, with a regulatory submitting anticipated in 2027, and a part 2 in Crohn’s illness additionally underway.
Nonetheless, the TL1A house has turn out to be one of the crowded in immunology: Merck, Sanofi/Teva, AbbVie, Spyre Therapeutics, and Boehringer Ingelheim are all pursuing the goal. And in June 2026, Merck introduced that its TL1A antibody tulisokibart had delivered the primary constructive part 3 leads to ulcerative colitis, beating Roche to the scientific milestone. Roche’s afimkibart had been seen as a frontrunner, however Merck has now moved forward. Roche’s filings are anticipated in 2027, which suggests it should doubtless be a second or third entrant, doubtlessly a special business proposition than the $7.1 billion worth tag, and making differentiation extra necessary than earlier than.
Cell remedy and neuroscience: Roche’s new bets and unfinished enterprise
The Poseida acquisition offers Roche one thing it didn’t have: a reputable allogeneic CAR-T platform. Present autologous CAR-T therapies require manufacturing a product from every affected person’s personal cells, which is time-consuming, costly, and logistically complicated. Allogeneic therapies use donor cells manufactured upfront, enabling quicker entry and doubtlessly decrease prices. Poseida’s lead candidate, P-BCMA-ALLO1, concentrating on a number of myeloma, confirmed a 91% total response charge in part 1 information in closely pretreated sufferers. The platform additionally has functions in autoimmune illness, an space of rising curiosity.
On the neuroscience facet, Roche has a painful historical past in neurodegeneration with gantenerumab failing in part 3 Alzheimer’s trials in 2022, following earlier setbacks with crenezumab and different pipeline candidates.
It’s on this context that Roche is advancing trontinemab, its subsequent Alzheimer’s candidate. Trontinemab is completely different from gantenerumab and makes use of Roche’s proprietary Brainshuttle know-how to hold the antibody throughout the blood-brain barrier through the transferrin receptor, attaining quicker and deeper amyloid clearance than prior antibodies. Part 2 information confirmed 91% of members grew to become amyloid PET-negative after six months. Two part 3 trials have been initiated, however the query can be whether or not amyloid clearance will translate to cognitive profit, which is the query that has challenged Alzheimer’s packages earlier than.
Then there’s Roche’s ambiguous Parkinson’s story with Prasinezumab for Parkinson’s. The part 2 Padova trial missed its major endpoint, however Roche has dedicated to part 3, citing that the totality of knowledge suggests the drug might be the primary disease-modifying candidate. That may be a defensible name given the near-total absence of disease-modifying choices in Parkinson’s, however it additionally requires the part 3 to ship the place the part 2 couldn’t.
A second reinvention for Roche
Roche navigated the biosimilar cliff by staying near what it knew: bispecific antibodies, lifecycle administration, and next-generation iterations in established biology. The technique now feels completely different as the corporate is stepping out of what it was constructed on. Weight problems, IBD, allogeneic cell remedy, and neurodegeneration are usually not extensions of an present franchise. They’re new territory and infrequently in markets which might be already aggressive and, in some circumstances, already transferring quicker than Roche anticipated.
The corporate is nicely established and has the monetary self-discipline, the infrastructure, and the dealmaking capabilities to compete. However this isn’t proof that the mixture thesis in weight problems will outpace Lilly and Novo Nordisk’s head begin, that afimkibart can differentiate in a TL1A discipline the place Merck has now moved first, or that trontinemab will turn out to be the Alzheimer’s success Roche has been on the lookout for.
Roche now seems to be like an organization constructed on oncology and diagnostics, reinventing itself throughout a number of therapeutic areas directly.
